Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies

Opinion
Video

Panelists discuss how isatuximab- and daratumumab-based quadruplet regimens compare in patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM), with a particular focus on minimal residual disease (MRD) negativity data from the IMROZ and CEPHEUS trials, presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition.

Video content above is prompted by the following:

  1. How do isatuximab-based regimens compare with daratumumab-based quadruplet regimens in patients with transplant-ineligible/deferred NDMM?
    1. Please comment on the latest results and approval from the IMROZ study evaluating Isa-VRd vs VRd in transplant-ineligible/deferred NDMM.
  2. What is the significance of MRD negativity as a primary outcome in studies presented at ASH 2024?
    1. CEPHEUS, MRD Negativity
    2. IMROZ, MRD Negativity
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.

Talquetamab Combo Data Warrant Further Research in R/R Multiple Myeloma

Russ Conroy
February 6th 2025
Article

Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

CAR T Therapy Shows Similar Efficacy, Safety in Multiple Myeloma Subgroups

Russ Conroy
February 2nd 2025
Article

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.

Response Depth in High-Risk Smoldering Multiple Myeloma May Predict Outcomes

Roman Fabbricatore
January 24th 2025
Article

Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.

Isatuximab Combo Approved in EU for Transplant-Ineligible NDMM

Isatuximab Combo Approved in EU for Transplant-Ineligible NDMM

Tim Cortese
January 22nd 2025
Article

Patients who received the isatuximab combination in the IMROZ trial experienced prolonged MRD-negativity, which correlated with improved PFS.